Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Thromboembolic Events in Castration‐Resistant Prostate Cancer Patients With and Without Cardiovascular Comorbidities Receiving Oral Androgen Receptor Pathway Inhibitors
Asiri, Ibrahim M. , Master, Viraj A. , Mi, Lanyu , James, Sarah E. , Bryce, Alan H. , Afzal, Umar, Naqvi, Syed Arsalan Ahmed , Cobran, Ewan K. , Ahmed Naqvi, Syed Arsalan, Cobran, Ewan K , Bryce, Alan H , Chen, Ronald C. , Afzal, Umar, Riaz, Irbaz Bin , Beach, Steven R. H.

Mayo Clinic

The Prostate | May 2, 2025 | Volume: 85 | Issue: 10 | Pages: 954-965

10.1002/pros.24902 | PMID 40312772 Get It

ABSTRACTBackgroundThis study investigates the association between thromboembolic events (TE) and castration‐resistant prostate cancer (CRPC) patients receiving oral androgen receptor pathway inhibitors (ARPi) compared to those undergoing chemotherapy, both with and without a pre‐existing history of cardiovascular disease (CVD).MethodsA total of 2779 men diagnosed with CRPC were identified using the Surveillance, Epidemiology, and End Results (SEER) Medicare Linked Database from 2012 to 2016. Patients were stratified based on their CVD history. Within each CVD stratum (pre‐existing CVD vs. no pre‐existing CVD), patients were further categorized into two treatment groups: those receiving oral ARPi and those undergoing chemotherapy. Unadjusted and inverse probability treatment weight (IPTW)‐adjusted proportional hazards models, using Fine and Gray's method, were applied to evaluate the potential association between ARPi treatment and TE.ResultsPatients with pre‐existing CVD treated with ARPi exhibited a significantly lower crude hazard ratio (HR) for TE compared to chemotherapy (HR 0.39, 95% CI 0.27–0.58, p < 0.001). However, after adjustment using IPTW, this association was no longer significant (adjusted hazard ratio [AHR] 1.00, 95% CI 0.75–1.32, p = 0.99). For patients without CVD, ARPi use was also associated with a reduced risk of TE in the crude analysis (HR 0.53, 95% CI 0.32–0.87, p = 0.01), but this effect was not statistically significant after IPTW adjustment (HR 0.99, 95% CI 0.69–1.41, p = 0.94).ConclusionARPi demonstrated no significant effect on TE risk compared to chemotherapy, regardless of pre‐existing CVD status. Similarly, when excluding patients with a prior history of TE, ARPi use remained non‐significantly associated with new TE in the IPTW‐adjusted competing risk analysis, highlighting the need for further investigation.
Abstract CT237: A randomized phase 2 non-inferiority trial of (Z)-endoxifen + goserelin and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE)
López, Clàudia, Erickson, Hayley, Nguyen, Lonnissa, Mina, Lida A. , Advani, Pooja , Leon‐Ferre, Roberto A. , Flora, Daniel , Jones, Jason M. , Hunt, Katie N. , Buhrow, Sarah A. , Schellenberg, Matthew J. , Hawse, John R. , Goetz, Matthew P. , Suman, Vera J. , López, Claudia S. , Erickson, Hayley, Hammer, Sandra S. , Giridhar, Karthik V. , Batalini, Felipe , Bagegni, Nusayba , Piltin, Mara A. , Degnim, Amy C. , Ingle, James N. , Boughey, Judy C. , Reid, Joel M. , Quay, Steven C.

Mayo Clinic

Cancer Research | April 25, 2025 | Volume: 85 | Issue: 8_Supplement_2 | Pages: CT237-CT237

10.1158/1538-7445.am2025-ct237 Get It

Abstract Background: Endocrine therapy (ET) with aromatase inhibitors (AI) plus ovarian function suppression (OFS) is standard for premenopausal women with ER+/HER2- breast cancer. However, many premenopausal women are intolerant of AI + OFS, leaving tamoxifen (with or without OFS) as their only option. Extensive studies have demonstrated that premenopausal women treated with neoadjuvant ET whose tumors exhibit Ki-67 ≤ 10% following 4 weeks of therapy (defined as endocrine sensitive disease (ESD)) achieve 5-year distant disease-free survival &gt; 96%. Problematically, only 41% of patients reach this ESD threshold with tamoxifen compared to 78% with AI+OFS (Nitz JCO 2022). (Z)-endoxifen (ENDX) is a potent selective estrogen receptor modulator (SERM) that inhibits ERα at plasma concentrations of 3-5 ng/ml and dually targets PKCβ1, a suspected oncogene in breast tumors, at concentrations ≥ 500 ng/ml. We therefore developed the EVANGELINE study (NCT05607004) is an open label, randomized neoadjuvant phase II study that includes a pharmacokinetic (PK) Run-in, aiming to evaluate whether ENDX +/- goserelin is non-inferior to exemestane plus goserelin with respect to ESD rate. Following the completed PK run-in portion of the study, where 40mg/day or 80mg/day ENDX were assessed, the 40 mg/day dose was selected for further evaluation in the second part of the trial. The second part is comprised of a randomized treatment cohort, for patients with a Ki-67% &gt;10% at preregistration randomized to either 40mg (Z)-endoxifen + goserelin or exemestane + goserelin neoadjuvant treatment and a Single Arm Treatment Cohort for patients who have a Ki-67 ≤ 10% at pre-registration assigned to 40mg/day (Z)-endoxifen monotherapy neoadjuvant treatment. Methods: To investigate ENDX further in premenopausal women, a multicenter study in the United States, was designed(EVANGELINE; NCT05607004). This phase 2, open-label, randomized, neoadjuvant trial includes a PK run-in phase designed to assess whether the 4-week ESD rate with (Z)-endoxifen + goserelin is non-inferior to that of exemestane + goserelin in premenopausal women with Stage IIA or IIB ER+/HER2- breast cancer with diagnostic Ki67 &gt; 10%. Additionally, a single arm Phase 2, open-label neoadjuvant Cohort was designed to assess the 4-week ESD rate with ENDX monotherapy in premenopausal women with Stage IIA or IIB ER+/HER2- BC with diagnostic Ki67 ≤10%. Subjects will undergo neoadjuvant treatment for six months before receiving surgical treatment in the involved breast. This study will additionally assess safety, tolerability, response rates, surgical outcomes, and monitor disease progression. Comprehensive biomarker evaluations will be conducted using paired tumor biopsies and blood samples collected at baseline and week four, as well as 6 month surgical specimens. Enrollment in the PK run-in phase (n-22) was completed in Fall 2024 with the second portion of the trial slated to begin early in 2025. Citation Format: Matthew P. Goetz, Vera J. Suman, Claudia Lopez, Hayley Erickson, Lonnissa Nguyen, Sandra S. Hammer, Lida Mina, Pooja Advani, Roberto Leon-Ferre, Karthik Giridhar, Felipe Batalini, Daniel Flora, Jason M. Jones, Nusayba A. Bagegni, Katie N. Hunt, Mara Piltin, Amy Degnim, James N. Ingle, Judy C. Boughey, Sarah A. Buhrow, Joel M. Reid, Matthew Schellenberg, John R. Hawse, Steven C. Quay. A randomized phase 2 non-inferiority trial of (Z)-endoxifen + goserelin and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT237.
Abstract CT079: Pharmacodynamic (PD) and exploratory biomarker (BM) analysis of the PRMT5 inhibitor BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del)
Simpson, Tyler R., George, Ben , Jänne, Pasi A. , Arbour, Kathryn C. , Leventakos, Konstantinos , Papadopoulos, Kyriakos P. , Perez, Cesar A. , Zuniga, Richard, Qin, Yidi, Chou, Wen-Chi, Olson, Peter , Anderes, Kenna , Wozniak, A., Chin, Curtis D., Henry, Jason T. , Rodon, Jordi , Johnson, Melissa L. , Spira, Alexander I. , Babiker, Hani M. , Haddox, Candace L. , Kumar, Tapsi , Chin, Curtis, Lei, Ming

Mayo Clinic

Cancer Research | April 25, 2025 | Volume: 85 | Issue: 8_Supplement_2 | Pages: CT079-CT079

10.1158/1538-7445.am2025-ct079 Get It

Abstract Background: Effective treatments (Tx) are needed for MTAP-del cancers (10-15% of all cancers). BMS-986504 (formerly MRTX1719) is a potential first-in-class MTA-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitor that selectively binds to the PRMT5-MTA complex, a synthetic lethal target in MTAP-del but not MTAP-wild-type cells. In the first-in-human phase 1/2 CA240-0007 study, BMS-986504 was well tolerated and showed clinical activity in heavily pretreated pts across multiple advanced solid tumors with homozygous MTAP-del. Here, we report results of exploratory PD analyses of PRMT5 inhibition with BMS-986504 in CA240-0007. Methods: Pts with advanced, unresectable or metastatic solid tumors with homozygous MTAP-del received BMS-986504 (50 to 800 mg) in 3-wk cycles. Symmetric dimethylarginine (SDMA) and intron retention are known PD BMs of PRMT5 inhibition. Therefore, PD effects of BMS-986504 were assessed via changes in plasma and tumor SDMA levels (mass spec and IHC), intron retention, and gene expression (RNASeq) based on samples collected at baseline (BL) and cycle 2 day 1 (C2D1). Additional analyses correlating efficacy outcomes with PD results and select mutations at BL were performed in clinically evaluable pts as of 19-SEP-24. Results: Robust PD modulation of the PRMT5 pathway was observed with BMS-986504. Among pts with matched samples (n = 63), median plasma SDMA levels were reduced by 56% from BL (122.6 ng/mL) to C2D1 (53.8 ng/mL). There were dose-dependent reductions in median plasma SDMA with the greatest reductions at 400 mg QD (59.7% [n = 20]), 400 mg BID (61.9% [n = 9]) and 600 mg QD (59.1% [n = 14]). These PD effects were corroborated in the tumor. Median tumor SDMA levels decreased from an HScore of 285 at BL to 0 at C2D1. Consistent with the SDMA decreases, increased intron retention was observed in 9/11 pts with matched samples. BMS-986504 led to downregulation of several gene pathways including DNA repair and mitotic spindle formation, and MYC and E2F targets, as assessed by RNASeq. There was no significant change in expression of MAT2A, PRMT5, or other PRMT genes, suggesting a lack of compensation for PRMT5 inhibition through these genes. Responses were observed with BMS-986504 across EGFR, KRAS, and TP53 mutation subgroups. Additional correlative analyses among BMs and efficacy outcomes will be presented. Conclusions: BMS-986504 demonstrated robust PD effects across multiple doses and solid tumors which is consistent with the proposed mechanism of action. There was a trend of increasing plasma SDMA reduction across doses, with the greatest reductions observed at 400 mg QD and above. Together these results support further investigation of BMS-986504 at 400 mg QD and higher doses as a potential first-in-class synthetic lethal Tx option in pts with advanced solid tumors with MTAP-del. Citation Format: Jordi Rodón, Tyler Simpson, Ben George, Pasi A. Jänne, Kathryn C. Arbour, Konstantinos Leventakos, Kyriakos P. Papadopoulos, Melissa L. Johnson, Alexander I. Spira, Cesar A. Perez, Hani M. Babiker, Richard Zuniga, Candace L. Haddox, Tapsi Kumar, Yidi Qin, Wen-Chi Chou, Peter Olson, Kenna Anderes, Alice Wozniak, Curtis Chin, Ming Lei, Jason T. Henry. Pharmacodynamic (PD) and exploratory biomarker (BM) analysis of the PRMT5 inhibitor BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion (MTAP-del) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr CT079.
Complex Metabolomic Changes in a Combined Defect of Glycosylation and Oxidative Phosphorylation in a Patient with Pathogenic Variants in PGM1 and NDUFA13
Radenkovic, Silvia , Adant, Isabelle , Bird, Matthew , Swinnen, Johannes V. , Cassiman, David , Ghesquière, Bart , Bird, Matthew J , Gruenert, Sarah C , Ghesquière, Bart , Kozicz, Tamás , Morava, Éva

Mayo Clinic

Cells | April 25, 2025 | Volume: 14 | Issue: 9 | Pages: 638

10.3390/cells14090638 | PMID 40358162 Get It

Inherited metabolic disorders (IMDs) are genetic disorders that occur in as many as 1:2500 births worldwide. Nevertheless, they are quite rare individually and even more rare is the co-occurrence of two IMDs in one individual. To better understand the metabolic cross-talk between glycosylation changes and deficient energy metabolism, and its potential effect on outcomes, we evaluated patient fibroblasts with likely pathogenic variants in PGM1 and pathogenic variants in NDUFA13 derived from a patient who passed away at 16 years of age. The patient presented with characteristic of PGM1-CDG including bifid uvula, muscle involvement, abnormal glycosylation in blood, and elevated liver transaminases. In addition, hearing loss, seizures, elevated plasma and CSF lactate and a Leigh-like MRI brain pattern were present, which are commonly associated with Leigh syndrome. PGM1-CDG has been reported in about 70 individuals, while NDUFA13 deficiency has so far only been reported in 13 patients. As abundant energy is essential for glycosylation, and both PGM1 and NDUFA13 are linked to energy metabolism, we sought to better understand the underlying biochemical cause of the patient’s clinical presentation. To do so, we performed extensive investigations including tracer metabolomics, lipidomics and enzymatic studies on the patient’s fibroblasts. We found a profound depletion of UDP-hexoses, consistent with PGM1-CDG. Complex I enzyme activity and mitochondrial function were also impaired, corroborating complex I deficiency and Leigh syndrome. Further, lipidomics analysis showed similarities with both PGM1-CDG and OXPHOS-deficient patients. Based on our results, the patient was diagnosed with both PGM1-CDG and Leigh syndrome. In summary, we present the first case of combined CDG and Leigh syndrome, caused by (likely) pathogenic variants in PGM1 and NDUFA13, and underline the importance of considering the synergistic effects of multiple disease-causing variants in patients with complex clinical presentation, leading to the patient’s early demise.
Asynchronous Technical Feedback: A Workshop for Training Surgical Instructors
Brian, Riley , Fernández, Úrsula Figueroa , Lund, Sarah , Cruz, Enrique , Navarro, Sergio M. , Varas, Julián , Navarro, Sergio Michael , Gomes, Camilla , Silvestri, Caitlin J. , Jarry, Cristián , O’Sullivan, Patricia

Mayo Clinic

MedEdPORTAL | April 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.15766/mep_2374-8265.11519 | PMID 40290420 Get It

Global Barriers to Otolaryngology Care
Patterson, Rolvix H. , Bangash, Ali Haider , Pandey, Akansha, Elwell, Zachary , Adeyemo, Adebolajo A. , Cahill, Gabrielle , Cherches, Alexander , Daudu, Davina , Der, Carolina , Din, Taseer , Hapunda, Racheal , Ibekwe, Titus , Maina, Ivy W. , Mukuzi, Allan, Nakku, Doreen , Petrucci, Beatriz, Pietrobon, Carolina, Salano, Valerie , Sprow, Holly N. , Waterworth, Christopher J. , Wiedermann, Joshua P. , Xu, Mary Jue , Alkire, Blake C., Okerosi, Samuel , Initiative, Global Otolaryngology–Head and Neck Surgery, Bhutta, Mahmood F. , Dillard, Lauren K. , Ncogoza, Isaie , Lin, H.C., Potent, Keith, Adel, Iman, Wiedermann, Joshua , Cherches, Alexander D , Din, Taseer , Ncogoza, Isaie , Bangash, Ali Haider , Patterson, Rolvix H , Zalaquett, Nader , Pandey, Akansha, Nuss, Sarah , Fei‐Zhang, David J. , Srinivasan, Tarika , Fagan, Johannes J. , Kahinga, Aveline Aloyce , Seguya, Amina , Shaye, David , Smith, Emily R. , Tamir, Sharon Ovnat , Wen, Christopher Z. , Initiative, Global Otolaryngology–Head and Neck Surgery, Shah, Keshav V. , Potent, Keith

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | April 24, 2025 | Volume: 151 | Issue: 6 | Pages: 604

10.1001/jamaoto.2025.0573 | PMID 40272811 Get It

ImportanceUnderstanding the global barriers to otolaryngology–head and neck surgery (OHNS) care is crucial in addressing disparities in access to care, particularly in low-income and middle-income countries (LMICs).ObjectiveTo characterize barriers to comprehensive otolaryngology care across World Bank income groups.Design, Setting, and ParticipantsUsing an online cross-sectional survey that was administered by the Global OHNS Initiative via international and national professional societies, personal contacts, and social media, this study captured the perceptions of otolaryngologists regarding barriers to OHNS care at the levels of the country, health sector, clinician, and patient. Participants included otolaryngologists from the 194 World Health Organization member states and Taiwan. Eligibility criteria included a medical degree and specialized training in managing conditions of the ear, nose, and throat. The nonresponse rate was not recorded. The data collection period spanned from October 2022 to June 2023.ExposuresExposures included World Bank income group classification.Main Outcomes and MeasuresThe primary outcomes were Likert scale responses regarding frequency of barriers to OHNS care. The a priori hypothesis was that LMICs would report more frequent barriers to OHNS care.ResultsThe study involved 146 otolaryngologists (47 female individuals [32%]), with 69 (47%) from high-income countries and 77 (53%) from LMICs. Male individuals represented 45 high-income country respondents (65%) and 54 LMIC respondents (70%). Barriers were reported across income groups at all levels of the health system, with a higher frequency in LMICs. Several barriers were reported to be more substantial in LMICs, such as the national volume and distribution of otolaryngologists, financial compensation for clinicians, and patient stigma, and others were common across income settings, such as the availability of operating rooms and inflexible working hours. Common concerns included national and health sector barriers: OHNS workforce, referral networks, government support; clinician barriers: excessive clinician workloads, understaffing, poor administration support; patient barriers: distance to health care facilities, financial burdens such as medical costs and foregone wages, stigma, and health literacy.Conclusions and RelevanceThe results of this cross-sectional study suggest that there are barriers to otolaryngology care globally that affected all levels of the health care system. This work may inform prioritization of otolaryngology within research and policy, and it emphasizes the need for effective strategies to expand access to otolaryngology care, particularly in lower-income settings.
Dysphagia and Mortality Risk in Individuals With Primary Progressive Apraxia of Speech
Meade, Gabriela , Pham, Nha Trang Thu, Boland, Sarah, Whitwell, Jennifer L. , Josephs, Keith A. , Boland, Sarah M, Whitwell, Jennifer , Josephs, Keith A , Meade, Gabriela , Clark, Heather M. , Duffy, Joseph R. , Botha, Hugo , Utianski, Rene L.

Mayo Clinic

Annals of Clinical and Translational Neurology | April 24, 2025 | Volume: 12 | Issue: 7 | Pages: 1493-1498

10.1002/acn3.70056 | PMID 40272101 Get It

ABSTRACTIndividuals with primary progressive apraxia of speech (PPAOS) often develop parkinsonism and dysphagia. To evaluate the clinical correlates and impact of dysphagia in this population, we compared enrollment visit data between individuals with (n = 12) versus individuals without (n = 44) dysphagia symptoms. The group with dysphagia had more motor speech symptoms and parkinsonism. Longitudinal analysis revealed that almost everyone developed dysphagia before dying; the average time to death after developing dysphagia was 5.43 years and complications of dysphagia resulted in mortality for 35% of the individuals for whom data were available. These results emphasize the need for dysphagia management and provide useful prognostic estimates.
Building an Interdisciplinary Workforce in Geroscience: Aligning Perspectives and Educational Goals
Al‐Naggar, Iman M. , Quinn, Crystal G, LaHue, Sara C. , Ocañas, Sarah R. , Yousefzadeh, Matthew J. , Kozikowski, Chester, McAbee‐Sevick, Heather, Curran, Sean P. , Justice, Jamie N. , Orr, Miranda E. , Thatcher, Christine, Espinoza, Sara , Newman, John C. , Pignolo, Robert J. , Yousefzadeh, Matthew J , Curran, Sean P , Justice, Jamie N , Newman, John C , Espinoza, Sara , Quinn, Crystal G, Campellone, Kenneth G. , Kuchel, George A.

Mayo Clinic

The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences | April 24, 2025 | Volume: 80 | Issue: 9 | Pages: No page available

10.1093/gerona/glaf090 | PMID 40850699 Get It

Abstract The National Institute on Aging-funded Geroscience Education and Training Network held the “Building an Interdisciplinary Workforce in Geroscience: Aligning Perspectives and Educational Goals” preconference workshop at the 2023 Gerontological Society of America’s Annual Meeting. Parties involved in geroscience education and interested stakeholders addressed the development of didactic educational materials, training, and career development opportunities to equip learners with the skills to meet the demands of the emerging field of geroscience, from research to clinic and industry. Recent successes were presented, existing opportunities, gaps, and challenges identified and discussed, and solutions and future directions described.
A mixed methods survey of research education requirements for residents in internal medicine, neurology and transitional programs
O’Shea, Michael , Ashcherkin, Nikita, Biondi, Matt , Chaffin, Hally, Umar, Sarah B. , Delafield, Nathan, Chhabra, Nikita, Hoerth, Matthew T., Starling, Amaal J. , Valles, Brittane T., Wu, Christina, Taylor, Gretchen, Hawkins, Camille, Persons, Patress , Biondi, Matthew, Umar, Sarah, Hoerth, Matthew, Starling, Amaal, Valles, Brittane, Karikalan, Suganya Arunachalam , Biondi, Matt , Sharma, Umesh

Mayo Clinic

Medical Education Online | April 24, 2025 | Volume: 30 | Issue: 1 | Pages: No page available

10.1080/10872981.2025.2494579 | PMID 40271579 Get It

“Everything is electronic health record-driven”: the role of the electronic health record in the emergency department diagnostic process
James, Tyler G. , Mangus, Courtney W. , Parker, Sarah J. , Cassady, Caitlin M. , Bellolio, Fernanda , Singh, Hardeep , Mahajan, Prashant , Singh, Hardeep , Bellolio, M Fernanda , Chandanabhumma, P. Paul , Pasupathy, Kalyan S. , Manojlovich, Milisa

Mayo Clinic

JAMIA Open | April 23, 2025 | Volume: 8 | Issue: 2 | Pages: No page available

10.1093/jamiaopen/ooaf029 | PMID 40270489 Get It

Abstract Objectives There is limited knowledge on how providers and patients in the emergency department (ED) use electronic health records (EHRs) to facilitate the diagnostic process. While EHRs can support diagnostic decision-making, EHR features that are not user-centered may increase the likelihood of diagnostic error. We aimed to identify how EHRs facilitate or impede the diagnostic process in the ED and to identify opportunities to reduce diagnostic errors and improve care quality. Materials and Methods We conducted semistructured interviews with 10 physicians, 15 nurses, and 8 patients across 4 EDs. Data were analyzed using a hybrid thematic analysis approach, which blends deductive (ie, using multiple conceptual frameworks) and inductive coding strategies. A team of 4 coders performed coding. Results We identified 4 themes, 3 at the care team level and 1 at the patient level. At the care team level, the benefits of the EHR in the diagnostic process included (1) customizing features to facilitate diagnostic workup and (2) aiding in communication. However, (3) EHR-driven protocols were found to potentially burden the care process and reliance on asynchronous communication could impede team dynamics. At the patient-level, we found that (4) patient portals facilitated meaningful patient engagement through timely delivery of results. Discussion While EHRs can improve the diagnostic process, they can also impair communication and increase workload. Electronic health record design should leverage provider-created tools to improve usability and enhance diagnostic safety. Conclusions Our findings have important implications for health information technology design and policy. Further work should assess optimal ways to release patient results via the EHR portal.